Multiple Sclerosis Spasticity

What it is

Spasticity is a common multiple sclerosis symptom involving involuntary muscle tightness or stiffness that can impair movement and quality of life.

Cannabis and cannabis-derived therapies

The 2017 NASEM consensus report found substantial evidence that oral cannabinoids improve patient-reported spasticity symptoms in adults with MS. Clinician-rated outcomes show smaller effects than patient-reported outcomes, suggesting a meaningful subjective benefit even where objective measures change less.

Multiple sclerosis context

Multiple sclerosis is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath surrounding nerve fibers. Clinical phenotypes include relapsing-remitting MS (most common, ~85% at diagnosis), secondary progressive MS, and primary progressive MS. Disease-modifying therapies (interferons, glatiramer acetate, fingolimod, ocrelizumab, ofatumumab, natalizumab, cladribine) reduce relapse frequency and slow disability accrual.

Spasticity is one of the most common symptoms across MS subtypes, affecting roughly 80% of patients at some point in the disease course. It results from upper-motor-neuron damage that disrupts inhibitory descending control of spinal motor neurons, producing involuntary muscle contractions, stiffness, painful spasms, and impaired motor function.

Cannabis is not a disease-modifying therapy for MS; it does not slow disease progression or prevent relapses. The clinical role is symptomatic management of spasticity and associated symptoms.

Nabiximols (Sativex) evidence

The strongest randomized-trial evidence for cannabis in MS spasticity comes from nabiximols (brand name Sativex), a 1:1 THC:CBD oromucosal spray standardized at 2.7 mg THC + 2.5 mg CBD per actuation. Nabiximols is approved in over 25 countries (UK, Canada, Germany, Spain, Italy, Australia, others) for MS spasticity. The US FDA has not approved nabiximols as of 2026.

Pivotal trials and pooled analyses:

• GW-1000 (2010-2014 series): consistent reduction in patient-reported spasticity NRS by 1-2 points (on a 0-10 scale) in patients refractory to first-line spasticity agents.
• MOVE-2 enriched-enrollment design: initial 4-week titration phase followed by randomized continuation only for responders. Responder population (roughly 40-50% of all enrollees) showed sustained spasticity-NRS improvement.
• Long-term safety extension data: generally favorable; adverse events include dizziness, fatigue, somnolence, oral discomfort, nausea, and occasional psychotropic effects.

Plant cannabis and oral cannabinoids in US patients

In the absence of FDA-approved nabiximols, US MS patients with spasticity have used:

• State medical-cannabis program products: oils, tinctures, capsules, and (less commonly) inhaled cannabis. Patient-reported benefit consistent with nabiximols trials, though standardization and dosing protocols differ from regulated pharmaceutical preparations.
• Dronabinol (Marinol): synthetic THC, FDA-approved for AIDS-associated anorexia and chemotherapy-induced nausea. Off-label use for MS spasticity is documented but not common.
• CBD-dominant preparations: sometimes used by patients who do not tolerate THC psychoactivity well. Evidence base is thinner; the nabiximols data combine THC + CBD.

Standard MS spasticity therapy

Cannabis is most often adjunctive to first-line spasticity therapy:

• Baclofen (oral or intrathecal pump): GABA-B agonist, mainstay therapy.
• Tizanidine: alpha-2 agonist; sedation can be limiting.
• Gabapentin or pregabalin: useful for spasm and neuropathic pain co-occurrence.
• Benzodiazepines (diazepam, clonazepam): for breakthrough spasm; tolerance limits chronic use.
• Dantrolene: direct muscle relaxant; hepatotoxicity monitoring required.
• Botulinum toxin: focal injection for specific muscle groups.
• Physical therapy and stretching: evidence-based, often combined with pharmacotherapy.

Cannabis combined with baclofen, tizanidine, or benzodiazepines produces additive CNS depression; dose adjustment of one or both is common.

Co-occurring MS symptoms with cannabis evidence

Cannabis may benefit several MS-associated symptoms beyond spasticity:

• Neuropathic pain: strong evidence per the NASEM chronic-pain finding; relevant for the substantial fraction of MS patients with central neuropathic pain.
• Sleep disturbance: common in MS; moderate evidence base for cannabis-related improvement.
• Bladder spasticity: patient-reported benefit; trial evidence is mixed.
• Fatigue: the most common MS symptom; cannabis effects are variable and dose-dependent (THC can paradoxically worsen fatigue at higher doses).
• Mood disorders: depression and anxiety are common in MS; cannabis effects are individual.
• Tremor: limited evidence for direct anti-tremor effect.

Drug interactions with disease-modifying therapies

Cannabis interactions with MS DMTs are not extensively characterized but several have theoretical relevance:

• Fingolimod: narrow therapeutic window; CBD CYP3A4 inhibition could affect levels.
• Cladribine, ocrelizumab, ofatumumab: B-cell-depleting therapies; cannabis-related immune-modulation effects are unclear but worth monitoring.
• Interferons: no significant interactions documented.
• Symptomatic medications: more relevant interactions (baclofen, tizanidine, benzodiazepines, gabapentinoids — all additive CNS depression).

Disease-course considerations

MS patients should not substitute cannabis for prescribed disease-modifying therapy. DMTs reduce annual relapse rate, MRI-measured disease activity, and long-term disability accrual through mechanisms unrelated to cannabis pharmacology. Cannabis is purely symptomatic.

Cannabis use should be coordinated with the neurologist managing DMT therapy, particularly during initiation of new DMTs or evaluation of DMT efficacy.

Practical guidance

• Start with low oral doses (THC 2.5-5 mg, CBD 5-20 mg) and titrate.
• Coordinate with the MS care team, particularly for patients on baclofen or tizanidine.
• Patients with significant cognitive symptoms may notice additive impairment from THC.
• Long-term cannabis use has the same risks as in other chronic conditions (cannabis use disorder, cognitive effects, respiratory effects if smoked).
• Patients should disclose cannabis use before any infusion procedure or surgery.

Related conditions

Many MS patients have chronic-pain and spinal-cord-injury-equivalent symptoms (central neuropathic pain, spasticity from upper-motor-neuron damage). The mmjnow library covers chronic-pain, peripheral-neuropathy, spinal-cord-injury, and ptsd as separate conditions with overlapping cannabis-evidence considerations relevant to many MS patients.